91 results on '"Perini, Guilherme Fleury"'
Search Results
2. Quality-of-life analysis of pembrolizumab vs brentuximab vedotin for relapsed/refractory classical Hodgkin lymphoma
3. How to manage lymphoid malignancies during novel 2019 coronavirus (CoVid-19) outbreak: a Brazilian task force recommendation
4. BCL-2 Inhibition as Treatment for Chronic Lymphocytic Leukemia
5. Everolimus as a single agent in refractory or relapsed Hodgkin's lymphoma: the Brazilian Named Patient Program Experience
6. Imbalance of Pro- and Anti-Inflammatory Cytokines in Patients With cHL Persists Despite Treatment Compared With Control Subjects
7. Pembrolizumab in relapsed or refractory primary mediastinal large B-cell lymphoma: final analysis of KEYNOTE-170
8. Accessing BTK Inhibitors and Other Novel Therapies for Mantle Cell Lymphoma: Are We All Invited to the Party?
9. BCL-2 as therapeutic target for hematological malignancies
10. Validating the Prognostic Value of Anemia and Thrombocytopenia in Latin American Patients with Diffuse Large B-Cell Lymphoma: A Study from the Grupo De Estudio Latinoamericano De Linfoproliferativos (GELL)
11. Evolution of Treatment Patterns and Prognostic Biomarkers in Latin American Patients with Chronic Lymphocytic Leukemia: A Study By the Grupo De Estudio Latinoamericano De Linfoproliferativos (GELL)
12. A life-threatening case of TAFRO syndrome with dramatic response to tocilizumab, rituximab, and pulse steroids: The first case report in Latin America
13. Fine and Gray or Cox model?
14. COVID-19 in patients with CLL: improved survival outcomes and update on management strategies
15. Brentuximab Vedotin in CD30+ Lymphomas
16. Primary CNS Lymphoma in Latin America: A Grupo De Estudio Latinoamericano De Linfoproliferativos (GELL) Survey in 80 Cancer Centers in Latin America
17. Validating the Halp Score (Hemoglobin,Albumin, Lymphocytes, and Platelets) and the Neutrophil/Lymphocyte Ratio ( NLR) As Prognostic Factors for Overall Survival in Patients with Diffuse Large B-Cell Lymphoma. Retrospective Analysis By the Grupo De Estudio De Latino America De Linfoproliferativos (GELL)
18. Impact of Cutaneous Involvement on the Clinical Outcome of Adult T-Cell Leukemia/Lymphoma: A Study from the Latin American Group of Lymphoproliferative Disorders (GELL)
19. Proposal of a Novel Latin American International Prognostic Index (LATAM-IPI) for Diffuse Large B-Cell Lymphoma (DLBCL) By the Grupo Para El Estudio De Linfoproliferativos En Latino-America (GELL)
20. Worldwide Examination of Patients with CLL Hospitalized for COVID-19
21. Epidemiology, Clinical Features, and Outcome of HTLV-1-Related Adult T-Cell Leukemia/Lymphoma in Latin America: A Study from the Latin American Group of Lymphoproliferative Disorders (GELL)
22. Alemtuzumab in the reversal of encephalopathy associated with hypereosinophilic syndrome
23. Diffuse Large B-Cell Lymphoma (DLBCL) in the Elderly: Real World Experience in Latin America. A Study from the Grupo De Estudio Latinoamericano De Linfoproliferativos (GELL)
24. Does Prompt Access to Healthcare Impact the Outcomes of Hodgkin Lymphoma? a Comparison between Public and Private Patients Sharing the Same Infrastructure
25. Progressive multifocal leukoencephalopathy in a patient with relapsed chronic lymphocytic leukemia treated with Ibrutinib
26. PET-CT Quantitative Parameter Delta Suvmax As a Predictor of Early Relapse in Patients with Difuse Large B-Cell Lymphoma
27. Serum Albumin and Neutrophil-to-Lymphocyte Ratio, Two Independent Factor Predicting Survival in Patients with Follicular Lymphoma: A Multi-Institutional Retrospective Cohort of 741 FL, from the Latin American Lymphoproliferative Study Group (GELL)
28. Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma.
29. COVID-19 in Patients with Lymphoma: A Grupo De Estudio Latinoamericano En Linfoproliferativos (GELL) Retrospective Study
30. Follicular Lymphoma in Latin America: Real-World Experience from 763 Patients
31. Effect of Pembrolizumab (Pembro) Monotherapy Versus Brentuximab Vedotin (BV) on Patients (Pts) with Relapsed/Refractory Classical Hodgkin Lymphoma (R/R cHL): Exploratory Analysis of the Randomized, Phase 3 Keynote-204 Study By Prior Lines of Therapy
32. New treatment approaches for relapsing/refractory Hodgkin's lymphoma: An overview of the Brazilian scenario.
33. Treatment patterns of Hodgkin's lymphoma in Brazil: experts' perspective.
34. Hodgkin's lymphoma unmet medical needs in Brazil: experts' perspective.
35. Not all that shines is cancer: pulmonary cryptococcosis mimicking lymphoma in [(18)] F fluoro-2-deoxy-D-glucose positron emission tomography
36. Not all that shines is cancer: pulmonary cryptococcosis mimicking lymphoma in [(18)] F fluoro-2-deoxy-D-glucose positron emission tomography
37. BELLWAVE-003: A phase 2 dose escalation, confirmation, and cohort expansion study of nemtabrutinib in hematologic malignancies.
38. Linfoma de Hodgkin e gestação: série de casos e proposta de protocolo para tratamento
39. Infarto cerebral agudo com distribuição marginal em paciente com síndrome hipereosinofílica
40. Post-Transplant Lymphoproliferative Disorders in Transplant Recipients: 14-Yr Experience at the Hospital Israelita Albert Einstein - Brazil
41. Autologous Stem Cell Transplantation (ASCT) As Upfront Treatment in Primary Central Nervous System Lymphoma (PCNSL): A Systematic Review and Comparative Analysis in Clinical Trials Setting
42. Early MMF Discontinuation Is an Effective and Safe Measure to Decrease CMV Reactivation in Patients Submitted to Unmanipulated Haploidentical Transplant with Post-Cy Immunosuppression
43. Clinical Outcome of 96 Post-Transplant Lymphoproliferative Disease Patients in a Renal Transplant Cohort
44. Lymphocyte/Monocyte Ratio (LMR) at Diagnosis Is Predictive of Survival with Post Transplant Lymphoproliferative Disease (PTLD) after Renal Transplant: An Analysis of 96 Patients of a Brazilian Cohort
45. Prognosis of Patients with Primary Central Nervous System Post-Transplant Lymphoproliferative Disorder (PTLD-CNS) Treated with Immunossupression Reduction, Intrathecal Chemotherapy and Whole-Brain Radiotherapy: An Analysis of 23 Patients in a Brazilian Cohort
46. Plasma cell leukemia
47. Impact of treatment on IL-4, IL-6, IL-10 and sCD25 levels in patients with Hodgkin’s Lymphoma
48. Genomic Profile of Patients with Triple Negative (JAK2, CALR and MPL) Essential Thrombocythemia and Primary Myelofibrosis
49. The Presence of ASXL1 Mutations As Well As a Total Number of Myeloid Driver Mutations Higher Than Two Is Strongly Associated with the Diagnosis of Primary Myelofibrosis As Opposed to Essential Thrombocythemia
50. Weight Gain in the First 10 Days after Hematopoietic Stem Cell Transplantation (HSCT) Is a Risk Factor for Early Mortality
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.